Cellares, an integrated development and manufacturing organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Bristol Myers Squibb will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership (TAP) program. As part of this expanded agreement, Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufa...